ImmunoGen falls after stopping Phase II lung cancer trial

ImmunoGen Inc. (NASDAQ:IMGN) fell $3.14 (19%) to $13.41 on Tuesday after discontinuing on the recommendation of an independent DMC the Phase II NORTH trial, which was evaluating the company's IMGN901 to treat small cell lung cancer (SCLC). The DMC said first-line treatment with IMGN901 plus etoposide and carboplatin was unlikely to demonstrate "sufficient improvement" on the primary endpoint of progression-free survival (PFS) vs. etoposide and carboplatin alone. Additionally, the DMC said all patients should discontinue IMGN901 due to an imbalance in the rate of infection and infection-related deaths between treatment arms. The open-label trial had enrolled over 135 patients with newly diagnosed SCLC. ...